Abstract
The MitraClip device was recently approved by the FDA for the management of severe degenerative mitral regurgitation in patients considered to be high risk for surgical repair or replacement of the mitral valve. The management of anti-platelet and anticoagulant therapy before, during, and after the MitraClip placement is not well defined given the lack of evidence from large randomized trials. In this paper, we propose practical management guidelines for using these agents.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
